Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation(HSCT)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Viral Infection After HSCT
- Sponsor
- Istituto Giannina Gaslini
- Enrollment
- 10
- Primary Endpoint
- Adverse events
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The aim of the study is to evaluate the adverse events and the efficacy of virus specific T lymphocytes selected in vitro from a family donor to treat some refractory viral infections as Adenovirus (ADV), Ebstein Barr virus (EBV), Cytomegalovirus (CMV) that developed in young patients (age between 0 and 21 years) after allogeneic hematopoietic cell transplantation (allo-HSCT) performed at the Transplant Clinical Unit of the IRCCS G. Gaslini Institute (IGG).
Detailed Description
The rationale for the study is based on the evidence that, despite the progress obtained in the management and prevention of viral infections in the patients who received allo-HSCT, some viral infections continue to be severe complications that may occurred before the immune recovery. Some of these viral reactivations are not responsive to the first or second line treatment and their treatment may be represent an important issue. The adoptive cellular immunotherapy based on the infusion of virus-specific T lymphocytes represent a valid therapeutic option and the quick access to this cellular therapy is crucial to prevent severe organ complications related to viral infection. In this study, the use of virus-specific T lymphocytes obtained from a seropositive family donor, briefly activated in vitro and immunomagnetically captured by their capacity to secrete IFN-gamma allows to obtain a rapidly usable T-lymphocyte population (both CD4+ and CD8+) potentially able to expand into the patient. The effectiveness, safety (peptides used are synthetic, no animal components, closed system production), good tolerance and speed of modality (less than 36 hours for production) is reported by many clinical studies.
Investigators
Maura Faraci
Principal investigator
Istituto Giannina Gaslini
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Absence of a suitable donor (seronegativity for the virus in question and / or failure to respond to the secretion test)
- •Patient with severe renal and/or hepatic impairment as specified above
- •Primary or secondary graft failure
- •Relapse of malignant underlying disease
Outcomes
Primary Outcomes
Adverse events
Time Frame: from day +1 of infusion until day +56
To collect any adverse event defined as any significant alteration of vital signs and / or organ function, expressed in clinical, hematochemical and radiological findings according to version 5 of the Common Terminology Criteria for Adverse Events (CTCAE)
Secondary Outcomes
- Specific cell viral immunity(from day +1 of infusion until day +56)
- Variation of viremia(from day +1 of infusion until day +56)
- Organ damage(from day +1 of infusion until day +56)
- Overall survival(from day +56 to 12 months)